Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service PFO & septal closure cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 96% on average (6 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 198 | 44% |
| 2020 | 1 | 181 | 47% |
| 2021 | 1 | 178 | 51% |
| 2022 | 0 | 139 | 54% |
| 2023 | 0 | 177 | 57% |
| 2024 | 1 | 171 | 59% |
| 2025 from claims | – | 188 152–221 | 59% |
| 2026 forecast | – | 192 151–242 | 60% |
| 2027 forecast | – | 197 146–260 | 60% |
| 2028 forecast | – | 201 142–277 | 61% |
| 2029 forecast | – | 205 140–295 | 61% |
| 2030 forecast | – | 210 138–312 | 62% |
Patent foramen ovale and atrial septal defect closure: mostly patients under 65. Professional codes (what the surgeon bills): CPT 93580.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Texas; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 17% inpatient hospital, 83% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 0 | 224+0.5%/yr | +0.5%/yr | 0.1 | 0% | 310 in 2030+5.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 422 | 17,591−6%/yr | −6%/yr | 6.61.1× | 5% | 20,600 in 2030+2.7%/yr |
| Structural heart (TAVR, TEER) | 191 | 3,813+6.2%/yr | +6.2%/yr | 1.50.9× | 0% | 6,400 in 2030+9%/yr |
| Mechanical circulatory support | 2 | 1,476−3.6%/yr | −3.6%/yr | 0.71.3× | 0% | 2,210 in 2030+6.9%/yr |
PFO & septal closure in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Abbott leads with 75% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 2 companies reported engagement with Texas’s surgeons worth $127K in consulting, speaking, meals and travel tied to these products, about $127K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.